These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 6432400

  • 21. Ceftazidime treatment in cystic fibrosis: resistant organisms in sputum and faeces.
    Dalzell AM, Sunderland D, Hart CA, Heaf DP.
    Thorax; 1991 Apr; 46(4):239-41. PubMed ID: 1903896
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Kinetic parameters of amikacin in cystic fibrosis children.
    Grenier B, Autret E, Marchand S, Thompson R.
    Infection; 1987 Apr; 15(4):295-9. PubMed ID: 3117703
    [Abstract] [Full Text] [Related]

  • 25. [Ceftazidime absorption into bronchial secretions in mucoviscidosis patients].
    Berthelot G, Lenoir G, Grenier B, Tournier G, Sardet A, Steru D, Bergogne-Berezin E.
    Pathol Biol (Paris); 1985 May; 33(5):430-4. PubMed ID: 3897974
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Pharmacokinetics of ceftazidime in normal and uremic subjects.
    Leroy A, Leguy F, Borsa F, Spencer GR, Fillastre JP, Humbert G.
    Antimicrob Agents Chemother; 1984 May; 25(5):638-42. PubMed ID: 6375562
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Theophylline disposition in cystic fibrosis.
    Isles A, Spino M, Tabachnik E, Levison H, Thiessen J, MacLeod S.
    Am Rev Respir Dis; 1983 Apr; 127(4):417-21. PubMed ID: 6838048
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis.
    Reid DW, Carroll V, O'May C, Champion A, Kirov SM.
    Eur Respir J; 2007 Aug; 30(2):286-92. PubMed ID: 17504792
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Experience with ceftazidime in cystic fibrosis.
    Dodge J, Zamiri I, Goodchild M, Ingram P.
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():325-9. PubMed ID: 6352637
    [Abstract] [Full Text] [Related]

  • 38. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
    Cantón R, Cobos N, de Gracia J, Baquero F, Honorato J, Gartner S, Alvarez A, Salcedo A, Oliver A, García-Quetglas E, Spanish Consensus Group for Antimicrobial Therapy in the Cystic Fibrosis Patient.
    Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Single-dose pharmacokinetics of cefsulodin in patients with cystic fibrosis.
    Reed MD, Stern RC, Yamashita TS, Ackers I, Myers CM, Blumer JL.
    Antimicrob Agents Chemother; 1984 May; 25(5):579-81. PubMed ID: 6732226
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.